 Biocept Inc NASDAQ:BIOC reported positive net income for the first half of 2021 as revenues rose due to the increased use of the firms COVID-19 RT-PCR tests, notably in the first quarter. In the six months to June 30 this year, the diagnostics group posted a net income of 772,000 compared to a net loss of 14.8 million in the same period of 2020 on revenue of 29.8 million, a large increase from the revenue figure of 2.4 million seen in the first half of 2020. 